                         SEQUENCE LISTING

<110>  Queen Mary University of London
 
<120>  Method for preventing or treating a protein aggregation disease

<130>  P105389PCT

<150>  GB 1412802.9
<151>  2014-07-18

<160>  12    

<170>  PatentIn version 3.5

<210>  1
<211>  40
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Oligo 18S 1129-69

<400>  1
gggcagcttc cgggaaacca aagtctttgg gttccggggg                             40


<210>  2
<211>  40
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Oligo No 4G 1129-69

<400>  2
ttaagggcat ctgatgcggc gcgtgacgcg gcgctaagtg                             40


<210>  3
<211>  88
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic oligomer Motif 1 Forward

<400>  3
gctaattttt gtatttttag tagctaattt ttgtattttt agtagctaat ttttgtattt       60

ttagtagcta atttttgtat ttttagta                                          88


<210>  4
<211>  88
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic oligomer Motif 1 Reverse

<400>  4
tactaaaaat acaaaaatta gctactaaaa atacaaaaat tagctactaa aaatacaaaa       60

attagctact aaaaatacaa aaattagc                                          88


<210>  5
<211>  88
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic oligomer Control 1 Forward

<400>  5
gagtaagaat ctattatata tggagtaaga atctattata tatggagtaa gaatctatta       60

tatatggagt aagaatctat tatatatg                                          88


<210>  6
<211>  88
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic oligomer Control 1 Reverse

<400>  6
catatataat agattcttac tccatatata atagattctt actccatata taatagattc       60

ttactccata tataatagat tcttactc                                          88


<210>  7
<211>  64
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic oligomer Motif 2 Forward

<400>  7
ggtgagtgtg agggtgggtg agtgtgaggg tgggtgagtg tgagggtggg tgagtgtgag       60

ggtg                                                                    64


<210>  8
<211>  63
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic oligomer Motif 2 Reverse

<400>  8
caccctcaca ctcaccaccc tcacactcac ccaccctcac actcacccac cctcacactc       60

acc                                                                     63


<210>  9
<211>  64
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic oligomer Control 2 Forward

<400>  9
actacaacgg gcccggccca atcacagctc gagcgccttg aatgacgtac tcatctctat       60

gcat                                                                    64


<210>  10
<211>  64
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic oligomer Control 2 Reverse

<400>  10
atgcatagag atgagtacgt cattcaaggc gctcgagctg tgattgggcc gggcccgttg       60

tagt                                                                    64


<210>  11
<211>  283
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Consensus AluSx repeat sequence

<400>  11
ggccgggcgc ggtggctcac gcctgtaatc ccagcacttt gggaggccga ggcgggcgga       60

tcacctgagg tcaggagttc gagaccagcc tggccaacat ggtgaaaccc cgtctctact      120

aaaaatacaa aaattagccg ggcgtggtgg cgcgcgcctg taatcccagc tactcgggag      180

gctgaggcag gagaatcgct tgaacccggg aggcggaggt tgcagtgagc cgagatcgcg      240

ccactgcact ccagcctggg cgacagagcg agactccgtc tca                        283


<210>  12
<211>  283
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  RNA consensus AluSx repeat sequence transcribed

<400>  12
ggccgggcgc gguggcucac gccuguaauc ccagcacuuu gggaggccga ggcgggcgga       60

ucaccugagg ucaggaguuc gagaccagcc uggccaacau ggugaaaccc cgucucuacu      120

aaaaauacaa aaauuagccg ggcguggugg cgcgcgccug uaaucccagc uacucgggag      180

gcugaggcag gagaaucgcu ugaacccggg aggcggaggu ugcagugagc cgagaucgcg      240

ccacugcacu ccagccuggg cgacagagcg agacuccguc uca                        283


